Home/Filings/4/0001123292-17-001162
4//SEC Filing

GENVEC INC 4

Accession 0001123292-17-001162

CIK 0000934473operating

Filed

Jun 19, 8:00 PM ET

Accepted

Jun 20, 4:34 PM ET

Size

11.3 KB

Accession

0001123292-17-001162

Insider Transaction Report

Form 4
Period: 2017-06-16
Transactions
  • Disposition to Issuer

    Common Stock

    2017-06-161,0610 total
  • Exercise/Conversion

    Stock Options (right to buy)

    2017-06-16$3.80/sh2,250$8,5500 total
    Exercise: $3.80From: 2017-06-16Exp: 2017-06-16Common Stock (2,250 underlying)
  • Exercise/Conversion

    Common Stock

    2017-06-16$3.80/sh+2,250$8,5502,250 total
  • Tax Payment

    Common Stock

    2017-06-16$7.19/sh1,189$8,5491,061 total
Footnotes (5)
  • [F1]Withholding of Common Stock to pay exercise price.
  • [F2]2. The shares of Common Stock were cancelled pursuant to the Agreement and Plan of Merger, dated January 24, 2017, among the Issuer, Intrexon Corporation ("Intrexon") and Intrexon GV Holding, Inc. (the "Merger Agreement") in exchange for (i) 315 shares of Intrexon common stock having a market value of $7,188 as of the close of trading on the date immediately prior to the effective date of the merger, and cash in lieu of fractional shares of Intrexon common stock, plus (ii) one contingent payment right (the "Merger Consideration").
  • [F3][footnote 2 continued] Each contingent payment right entitles the holder thereof to an amount equal to half of certain payments actually received by the registrant or its successor or any of their affiliates from or on behalf of Novartis Institutes for BioMedical Research, Inc. ("Novartis") under the Research Collaboration and License Agreement, dated January 13, 2010, as amended, between the registrant and Novartis, on account of milestone payments or royalties due in relation to the period ending June 16, 2019, divided by the number of shares of the regisrant's common stock having rights to the Merger Consideration, subject to any withholding of taxes required by applicable law.
  • [F4]Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration.
  • [F5]Pursuant to the Merger Agreement, the vesting date of unvested stock options accelerated to vest and become exercisable as of the closing of the merger.

Issuer

GENVEC INC

CIK 0000934473

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000934473

Filing Metadata

Form type
4
Filed
Jun 19, 8:00 PM ET
Accepted
Jun 20, 4:34 PM ET
Size
11.3 KB